Ionis Pharmaceuticals, Inc. (IONS) announced that Pfizer (PFE) reported positive results from Phase 2b clinical study of vupanorsen. Based in California, Ionis Pharmaceuticals is a biotechnology company that specializes in discovering and developing human therapeutic drugs. Vupanorsen, earlier known as IONIS-ANGPTL3-LRx, is an investigational antisense therapy, and is being developed for indications in cardiovascular risk reduction and severe hypertriglyceridemia. In November 2019, Pfizer licensed vupanorsen from Ionis in a worldwide exclusive agreement.  See Insiders’ Hot Stocks on TipRanks >> Results of the Study Notably, the study met its primary endpoint by achieving statistically significant reduction in non-high-density lipoprotein cholesterol (non-HDL-C) compared to placebo at all doses tested at 24 weeks.
https://www.tipranks.com/news/ionis-reveals-results-study-of-vupanorsen?utm_source=advfn.com&utm_medium=referral
Ionis Pharmaceuticals (NASDAQ:IONS)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Ionis Pharmaceuticals Charts.
Ionis Pharmaceuticals (NASDAQ:IONS)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Ionis Pharmaceuticals Charts.